Drug-induced hypersensitivity syndrome like reaction with angioedema and hypotension associated with BRAF inhibitor use and antecedent immune checkpoint therapy
Main Authors: | Jasmine Rana, MD, Nolan J. Maloney, MD, Kerri E. Rieger, MD, PhD, Silvina B. Pugliese, MD, Jenna L. Strelo, MSN, RN, Anne Liu, MD, Lisa C. Zaba, MD, PhD, Bernice Y. Kwong, MD |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-07-01
|
Series: | JAAD Case Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2352512621003179 |
Similar Items
-
Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing
by: Gulietta M. Pupo, et al.
Published: (2017-05-01) -
Durable Response to Combined Dabrafenib and Trametinib in a Patient With BRAF K601E Mutation-Positive Lung Adenocarcinoma: A Case Report
by: Po-Lan Su, MD, et al.
Published: (2021-08-01) -
Cutaneous Langerhans cell histiocytosis with gastrointestinal involvement treated with dabrafenib
by: Jacob R. Stewart, BS, et al.
Published: (2018-01-01) -
Dabrafenib: a new opportunity for the treatment of BRAF V600-positive melanoma
by: Banzi M, et al.
Published: (2016-05-01) -
Population Pharmacokinetics/Pharmacodynamics of Dabrafenib Plus Trametinib in Patients with BRAF-Mutated Metastatic Melanoma
by: David Balakirouchenane, et al.
Published: (2020-04-01)